

# Clinical performance of SARS-COV-2 antibody tests varies

May 21 2020

---



(HealthDay)—The diagnostic specificity of severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) serologic assays varies, and sensitivity is poor during the first 14 days of symptoms, according to a study published online May 13 in *Clinical Chemistry*.

Mei San Tang, M.D., from the Washington University School of Medicine in St. Louis, and colleagues compared two commercial SARS-CoV-2 immunoglobulin G assays. A total of 103 specimens from 48 patients with [polymerase chain reaction](#)-confirmed SARS-CoV-2 infections and 153 control specimens were analyzed using serologic assays by Abbott and EUROIMMUN.

The researchers found that the Abbott SARS-CoV-2 [assay](#) had diagnostic specificity of 99.4 percent and sensitivity of 0.0, 30.0, 47.8, and 93.8 percent at less than three, three to seven, eight to 13, and  $\geq 14$  days post-[symptom onset](#). On the EUROIMMUN assay, diagnostic specificity was 94.8 and 96.7 percent if borderline results were considered positive and negative, respectively. If borderline results were considered positive, the diagnostic sensitivity was 0.0, 25.0, 56.5, and 85.4 percent at less than three, three to seven, eight to 13, and  $\geq 14$  days, respectively. The qualitative concordance was 0.83 between the assays.

"Our results also demonstrate low sensitivity for detecting SARS-CoV-2 antibodies before 14 days post-symptom onset on both assays," the authors write. "This argues that serologic status should not be assessed until 14 days post-symptom onset and confirms that molecular assays should remain the primary method for COVID-19 diagnosis."

One author disclosed financial ties to the biotechnology industry.

**More information:** [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Clinical performance of SARS-COV-2 antibody tests varies (2020, May 21) retrieved 9 September 2024 from

<https://medicalxpress.com/news/2020-05-clinical-sars-cov-antibody-varies.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.